Drugs / MEDI1814
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02036645 | Feb 2014 → Sep 2016 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-07-12 | Eli Lilly and Company | Results Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017) lilly.com ↗
MEDI1814, a High-Affinity Antibody Directed to the C-Terminus of Aßx-42, Abrogates Synaptic Plasticity Disruption Caused By Synthetic or AD Brain-Derived Aß Soluble Assemblies In Vivo |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-07-12 | Eli Lilly and Company | Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017) lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI1814 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02036645 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody for IV Injection” NCT02036645 ↗ |
| Route | Intravenous | “dosed by IV injection” NCT02036645 ↗ |